These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33728938)

  • 1. Inhibitor of DNA-binding family regulates the prognosis of ovarian cancer.
    Zhou Q; Mei YD; Yang HJ; Tao YL
    Future Oncol; 2021 May; 17(15):1889-1906. PubMed ID: 33728938
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.
    Tian X; Han Y; Yu L; Luo B; Hu Z; Li X; Yang Z; Wang X; Huang W; Wang H; Zhang Q; Ma D
    Cancer Biol Ther; 2017 Apr; 18(4):245-251. PubMed ID: 28346042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of inhibitor of differentiation/DNA-binding gene family in lung cancer using bioinformatics methods.
    Xu S; Wang Y; Li Y; Zhang L; Wang C; Wu X
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32003423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian Cancer by Bioinformatics Analysis.
    Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
    Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Expression of
    Zou R; Xu H; Li F; Wang S; Zhu L
    DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
    Sun T; Bi F; Liu Z; Yang Q
    Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-Omics Analysis Identifying Key Biomarkers in Ovarian Cancer.
    Li JY; Li CJ; Lin LT; Tsui KH
    Cancer Control; 2020; 27(1):1073274820976671. PubMed ID: 33297760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
    Diao B; Yang P
    Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis.
    Cao T; Pan W; Sun X; Shen H
    J Ovarian Res; 2019 Oct; 12(1):101. PubMed ID: 31656201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
    Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
    J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic values of S100 family members in ovarian cancer patients.
    Bai Y; Li LD; Li J; Lu X
    BMC Cancer; 2018 Dec; 18(1):1256. PubMed ID: 30558666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic roles of Notch receptor mRNA expression in human ovarian cancer.
    Chen C; Wang X; Huang S; Wang L; Han L; Yu S
    Oncotarget; 2017 May; 8(20):32731-32740. PubMed ID: 28415574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
    Zhou X; Teng L; Wang M
    Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
    Bai Y; Li LD; Li J; Lu X
    J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer.
    Zheng R; Chen W; Xia W; Zheng J; Zhou Q
    Biomed Res Int; 2020; 2020():7658782. PubMed ID: 33282953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression and prognosis of sirtuin family members in ovarian cancer.
    Zeng Z; Huang Y; Li Y; Huang S; Wang J; Tang Y; Jiang Y
    Medicine (Baltimore); 2020 Jun; 99(24):e20685. PubMed ID: 32541517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
    Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
    J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic values of S100 family mRNA expression in ovarian cancer.
    Ma N; Zhu L; Yang L; Cui Y; Zhan Y
    Cancer Biomark; 2019; 25(1):67-78. PubMed ID: 31033462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer.
    Jia W; Chang B; Sun L; Zhu H; Pang L; Tao L; Zou H; Du J; Dong Y; Qi Y; Jiang J; Liang W; Li F; Zhao X
    Int J Clin Exp Pathol; 2014; 7(9):5940-9. PubMed ID: 25337238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
    Chen H; Tian X; Luan Y; Lu H
    Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.